Join us this March for the first ever CURE Patient-Focused Sessions, taking place at the Miami Breast Cancer Conference! 

×
To start your customized experience click the start button
Customize ?  
Start
Cancer Types
Quick Links
Award Programs
About Us
Careers
Contact Us
Newsroom
Privacy Policy
Terms & Conditions
 
Twitter
Face Book
YouTube
Instagram
 
 
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2018
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.

Cure Connections

Meryl Kaufman, M.Ed., CCC-SLP, BRS-S, and Itzhak Brook, M.D., M.Sc., board members of the Head and Neck Cancer Alliance, provide their perspectives on adjusting to life with cancer of the head and neck, as a patient or as a caregiver, and share advice for those who must undergo laryngectomy. 
Meryl Kaufman, M.Ed., CCC-SLP, BRS-S, and Itzhak Brook, M.D., M.Sc., board members of the Head and Neck Cancer Alliance, share insight into the role of novel treatment approaches like immunotherapy, robotic surgery and de-escalation in the management of cancers of the head and neck.
Meryl Kaufman, M.Ed., CCC-SLP, BRS-S, and Itzhak Brook, M.D., M.Sc., board members of the Head and Neck Cancer Alliance, review the various modalities of treatment for cancers of the head and neck and identify which physicians are responsible for delivering this care.
Itzhak Brook, M.D., M.Sc., considers how experiencing cancer of the head and neck as a patient affected his understandings as a physician and outlines available patient resources with fellow board member of the Head and Neck Cancer Alliance, Meryl Kaufman, M.Ed., CCC-SLP, BRS-S.
More

Cure Expert Connections

Looking to future therapeutic approaches and combinations, Joyce A. O’Shaughnessy, MD, reflects on the potential role of poly ADP ribose polymerase (PARP) inhibition for BRCA-positive breast cancer management.
 
Joyce A. O’Shaughnessy, MD, provides insight on the available poly ADP ribose polymerase (PARP) inhibitors with regard to their safety profiles and the rationale behind their development for BRCA-positive breast cancer.
Joyce A. O’Shaughnessy, M.D., provides considerations for the prevalence of BRCA mutations in human epidermal growth factor receptor 2 (HER2)-negative breast cancer and elucidates the role of mutational analysis in this setting.
 
Specifically looking into the human epidermal growth factor receptor 2 (HER2)-negative breast cancer setting, Joyce A. O’Shaughnessy, M.D., considers what treatment options were historically available for patients.
More

Cure TV

Peter Voorhees, M.D.
New findings could spark change in the way that some patients with multiple myeloma are treated.
Matthew Yurgelun, M.D.
There can be many benefits for patients with gastrointestinal cancers, as well as their loved ones, to undergo genetic testing.
William P. Harris, M.D.
An expert describes what an interventional clinical trial is.
Shannon Pulaski
A cancer diagnosis can lead to discussions about family health history, as well as a whole new world to learn about.
More
×
×

Sign In

Not a member? Sign up now!
Continue without login
Continue
×

Sign Up

Patient Caregiver Advocate Other